Synthetic Cannabinoids: A Teen's Death and the Unintended Consequences of Drug Policy
"How Norwegian cannabis policy indirectly led to a tragic death and highlighted the dangers of synthetic alternatives."
In 2015, Egil André Kvelstad Myhre, a 22-year-old Norwegian, tragically passed away from cardiac arrest after experimenting with synthetic cannabinoids. This event, initially reported as an isolated incident, exposed a darker side of drug policy and its unintended consequences.
Myhre, described by his family as someone with no prior drug use, attended a party where he was introduced to a synthetic cannabinoid. The forensic report identified the substance as MBDB, closely related to MDMA. While others at the party also experimented, Myhre's reaction was uniquely fatal.
The case became the first registered fatality in Norway linked to synthetic cannabinoids. National newspapers covered the story as a warning about the dangers of these new and unstable drugs, quoting doctors, police, and health officials who cautioned the public. However, crucial details emerged that painted a more complex picture, revealing the hidden link between drug policy and this tragic outcome.
The Dealer's Story: Apology and a Call for Legalization

A local newspaper, "Trønder-avisa," interviewed the dealer, named "Ørjan," who sold the drug to Myhre's acquaintance. Ørjan claimed to have been selling synthetic drugs for years, with sales volume inversely related to the availability of organic cannabis. He sourced the drugs online, crossing the border to Sweden to pick them up.
- Desire to apologize to Myhre's family.
- Hopes to ignite debate on cannabis legalization.
- Claims he wouldn't share drug with inexperienced users.
A Preventable Tragedy?
Myhre's death highlights the unintended consequences of strict cannabis policies. The pursuit of alternatives like synthetic cannabinoids, driven by the need to circumvent drug testing, can lead to devastating outcomes. As long as cannabis remains illegal, the allure of unregulated and potentially lethal synthetic alternatives will persist, putting vulnerable individuals at risk. The tragic loss of Egil André Kvelstad Myhre serves as a stark reminder of the need for evidence-based drug policies that prioritize harm reduction and public health.